Keyphrases
Anticancer Drugs
100%
Tissue Injury
100%
Toxicity Profile
75%
Systemic Toxicity
75%
Whole-body
75%
Therapeutic Regimen
50%
Apoptosis
50%
Duramycin
50%
Apoptosis Imaging
25%
Oncology Patients
25%
Clearance Kinetics
25%
Drug Tolerance
25%
New Anticancer Drugs
25%
Anticancer Drug Combinations
25%
Multi-organ
25%
Drug Combination
25%
Imaging Applications
25%
Dead Cells
25%
Toxicity Evaluation
25%
Dying Cells
25%
New Combination
25%
Pharmaceutical Development
25%
Radiopharmaceuticals
25%
Whole-body Scan
25%
New Drug Candidate
25%
Organ Index
25%
Imaging Agents
25%
Therapy Optimization
25%
Anticancer Treatment
25%
Binding Affinity
25%
Adverse Effects
25%
Clinically Significant
25%
Whole-body Imaging
25%
Cell Death
25%
Tumor Cells
25%
Doxorubicin
25%
Multiple Tissues
25%
Combination Treatment
25%
Phosphatidylethanolamine
25%
Prognostic Indicator
25%
Existing Drugs
25%
Medicine and Dentistry
Tissue Injury
100%
Anticarcinogen
100%
Programmed Cell Death
75%
Lancovutide
50%
Technetium-99
50%
Imaging Agent
25%
Antiinfective Agent
25%
Whole Body Imaging
25%
Whole Body Scintiscanning
25%
Tumor Cell
25%
Binding Affinity
25%
Adverse Event
25%
Radiopharmaceutical Agent
25%
Oncology
25%
Diagnosis
25%
Cell Death
25%
Phosphatidylethanolamine
25%
Drug Tolerance
25%
Combination Drug
25%
Doxorubicin
25%
Pharmacology, Toxicology and Pharmaceutical Science
Tissue Injury
100%
Anticarcinogen
100%
Technetium 99m
50%
Lancovutide
50%
Doxorubicin
25%
Drug Tolerability
25%
Antiinfective Agent
25%
Adverse Event
25%
Radiopharmaceutical Agent
25%
Phosphatidylethanolamine
25%
Combination Drug
25%
Neoplasm
25%